CAR Ts and BiTEs Shine in Multiple Myeloma.

Abstract

Chimeric antigen receptor T-cell treatments and bispecific T-cell engager therapies are showing evidence of efficacy in relapsed or refractory multiple myeloma in early trials, but so far neither therapeutic strategy has outshined the other.